Sarepta falls as article questions eteplirsen study

Shares of Sarepta Therapeutics (SRPT -7.1%) are down sharply in morning trading.

The catalyst for the move looks to be an article by SA contributor EnhydrisPECorp who, according to the disclosure statements, was long SRPT last month and is now short.

Essentially, the piece attacks the small sample size of the eteplirsen Phase 2 trial and questions if it was appropriate (from a statistical perspective) to deem two patients outliers for the purpose of evaluating ambulatory performance even though they demonstrated "dramatic increases in dystrophin production."

Incidentally, SA contributor Steven Breazzano also published a bearish piece on SRPT today.

From other sites
Comments (3)
  • largrasr
    , contributor
    Comments (4) | Send Message
    The enlargements raised are not new, and have been part of the investment decision criteria for some time, The analysis provided is complex and it would behoove the company to challenge the accuracy of the articles. We know that SRPT is heavily shorted and I am suspicious of "authors" who write negative reports while shorting the stock.
    As I have done since I bought my initial positions at $2.40, I will look for a rebuttal or more corroboration. As of this writing, I am seriously thinking of adding to my positions.
    30 Oct 2013, 12:54 PM Reply Like
  • Miguelos
    , contributor
    Comments (4) | Send Message
    O.K. I have a M.A. in Economics, own SRPT shares, have worked over 20 yrs. in the pharmaceutical industry so that the attacks that intend to pass as pseudo scientific by people who, to boot, say that they are short on SRPT are not surprising. To me SRPT is the TSLA of the Biopharma industry. Both their respective CEO´s are remarkably alike in style and in the profound knowledge of their own métier. Their unorthodox approach irritates critics and rivals with an ax to grind. Their answer is to contribute to the volatility of stocks that promise big gains and solace to the investor. TSLA has proven so far to be nearly bullets proof. SRPT, not a single product outfit, will probably join the ranks of the innovators as soon as the FDA closes the issue for good to the chagrin of the fear mongers. Meanwhile I´ll keep my SRPT shares growing knowing that the going will continue to be rough until most of the faint hearted are out of the way.
    30 Oct 2013, 10:59 PM Reply Like
  • freelance writer
    , contributor
    Comments (2) | Send Message
    I followed the link from the article on the Neurology paper. I than went to, the horses mouth. And I found nothing that collaborated the negative claims of the article.
    31 Oct 2013, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs